In acute lymphoblastic leukemia, curcumin (15 μM) enhanced the apoptotic effects induced by imatinib (1 μM) on SUP-B15 cells through the downregulation of the Akt/mTOR pathway and the upregulation of the Bax/Bcl-2 ratio. Here, BCL2 is linked to acute lymphoblastic leukemia.